{"id":"sup-lidocaine","safety":{"commonSideEffects":[{"rate":null,"effect":"Local irritation or burning at application site"},{"rate":null,"effect":"Allergic contact dermatitis"},{"rate":null,"effect":"Systemic toxicity (if absorbed in large quantities)"}]},"_chembl":{"chemblId":"CHEMBL79","moleculeType":"Small molecule","molecularWeight":"234.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lidocaine works by inhibiting the influx of sodium ions through voltage-gated sodium channels in nerve fibers, thereby preventing depolarization and blocking the generation and conduction of action potentials. This results in local anesthesia at the site of application. The SUP formulation (likely a suppository or specialized delivery system) allows for localized pain relief in specific anatomical regions.","oneSentence":"SUP Lidocaine is a topical formulation of lidocaine, a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:10:08.449Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Localized pain relief (specific indication dependent on SUP formulation type)"}]},"trialDetails":[{"nctId":"NCT02270255","phase":"PHASE2","title":"Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2015-04","conditions":"Leiomyoma","enrollment":44},{"nctId":"NCT01496846","phase":"PHASE4","title":"Efficacy Study of Articaine Versus Lidocaine as Supplemental Infiltration in Inflamed Molars","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2011-09","conditions":"Irreversible Pulpitis","enrollment":201}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Generic lidocaine (Henry Schein Inc)"],"phase":"marketed","status":"active","brandName":"SUP Lidocaine","genericName":"SUP Lidocaine","companyName":"University of Michigan","companyId":"university-of-michigan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SUP Lidocaine is a topical formulation of lidocaine, a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission. Used for Localized pain relief (specific indication dependent on SUP formulation type).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}